{
  "docId": "019de514-c6ee-70fe-9ed1-115332e66453",
  "docSlug": "7d8148a830366811cd98c46e453c2fa7",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 10 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 10,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-c6ee-70fe-9ed1-115332e66453/4",
  "deckHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453",
  "deckJsonHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453.json",
  "deckAnchorHref": "/decks/019de514-c6ee-70fe-9ed1-115332e66453#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.57,
        "w": 0.36,
        "x": 0.53,
        "y": 0.33
      },
      "kind": "chart",
      "text": "~10 million B Cells, 667 RBD binders, 311 neutralizers, 171 non-convergent clones, 60 high potency, 31 broad VOC binders, 6 low risk escape, NVD200 + Other Candidates",
      "attrs": {},
      "subkind": "funnel",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c49e751c-1be1-44b7-b552-1fbd19ed47a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.405,
        "x": 0.045,
        "y": 0.57
      },
      "kind": "list",
      "text": "Pinpoint dominant spike protein sites targeted by human antibody repertoires and map common mutational escape routes to predict future variants",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33085cdb-15b7-42b1-8054-d7c93fae2bf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.405,
        "x": 0.045,
        "y": 0.78
      },
      "kind": "list",
      "text": "Identify potent mAb candidates that target rare epitopes not under strong immune pressure",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46b49587-635c-4950-9a97-466c8d9adaa2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.405,
        "x": 0.045,
        "y": 0.39
      },
      "kind": "list",
      "text": "Mine human antibody repertoires induced following contemporary SARS-CoV-2 exposures",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50a493cf-88aa-4955-9ccd-97bff82e2225",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.84,
        "x": 0.045,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc2ad15c-5496-40dd-9827-fd58bc101177",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.018,
        "x": 0.95,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "10",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef8c6df6-0ace-4434-8617-4860203914c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.108,
        "w": 0.84,
        "x": 0.045,
        "y": 0.07
      },
      "kind": "title",
      "text": "INVIVYD IN ACTION: APPROACH TO SELECTION OF NEXT GENERATION COVID-19 PRODUCT CANDIDATES",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c71c569b-476c-4ffe-85ee-fc7e0190bfd8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "53cce847-df69-48c9-abb8-2a4b649b65ab",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The discussion of the challenge of rapidly evolving variants",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "82a8193a-fe63-44e6-9054-8fee1a4a2720",
      "evidence": "The discussion of the challenge of rapidly evolving variants and the need for adaptable treatments",
      "position": 0,
      "objective": "What is the cost of not having effective treatments for COVID-19?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}